Related Experiment Video

Updated: Aug 17, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

[The effect of carvedilol on apoptosis gene PDCD5 expression in chronic heart failure patients]

Yan Wu1, Xiao-Yun Nie, Da-Yi Hu

  • 1People's Hospital, Peking University, Beijing 100044, China.

Zhonghua Yi Xue Za Zhi
|June 4, 2005
PubMed

Insights

Serum PDCD5 antibody levels are elevated in chronic ischemic heart failure patients. Carvedilol treatment significantly reduced these antibody levels and improved cardiac function, indicating its therapeutic potential.

Area of Science:

  • Cardiology
  • Immunology
  • Molecular Biology

Background:

  • Chronic ischemic heart failure is associated with complex pathophysiological changes, including apoptosis.
  • The role of programmed cell death protein 5 (PDCD5) and its antibody in heart failure pathogenesis requires further elucidation.
  • Understanding the impact of therapeutic interventions on apoptotic markers is crucial for managing heart failure.

Purpose of the Study:

  • To investigate serum levels of PDCD5 antibody in patients with chronic ischemic heart failure.
  • To evaluate the effect of carvedilol treatment on serum PDCD5 antibody titers and cardiac function parameters.

Main Methods:

  • A cohort of 20 chronic ischemic heart failure patients (LVEF < 45%, NYHA II-III) received carvedilol for 6 months.
  • Serum PDCD5 antibody levels were measured using ELISA before and after treatment.
  • Comparisons were made with serum levels from 20 healthy individuals; cardiac function (LVEF, chamber dimensions) and NYHA class were assessed.

Main Results:

  • Patients with chronic ischemic heart failure exhibited significantly higher serum PDCD5 antibody levels compared to healthy controls (P < 0.01).
  • Carvedilol treatment led to a significant reduction in serum PDCD5 antibody levels (P < 0.05).
  • Carvedilol therapy improved cardiac function, evidenced by increased LVEF (35.5% to 42.7%, P < 0.05) and decreased ventricular diameters, along with a slight improvement in NYHA class (P < 0.05).

Conclusions:

  • Elevated serum PDCD5 antibody titers are associated with chronic ischemic heart failure, suggesting a role for apoptosis.
  • Carvedilol treatment effectively reduces PDCD5 antibody levels in these patients.
  • The observed improvements in cardiac function underscore carvedilol's therapeutic benefits in chronic ischemic heart failure.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...